Legal & General Group
MYGN icon

Legal & General Group’s Myriad Genetics MYGN Stock Holding History

Legal & General Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Sell
21,005
-38,698
-65% -$176K ﹤0.01% 2619
2026
Q1 		$269K Sell
59,703
-160,769
-73% -$838K ﹤0.01% 2485
2025
Q4 		$1.36M Sell
220,472
-12,814
-5% -$92.9K ﹤0.01% 2125
2025
Q3 		$1.69M Sell
233,286
-4,402
-2% -$26.1K ﹤0.01% 2050
2025
Q2 		$1.26M Buy
237,688
+2,313
+1% +$13.7K ﹤0.01% 2167
2025
Q1 		$2.09M Sell
235,375
-10,771
-4% -$129K ﹤0.01% 1906
2024
Q4 		$3.37M Buy
246,146
+2,635
+1% +$48.6K ﹤0.01% 1756
2024
Q3 		$6.67M Sell
243,511
-3,694
-1% -$100K ﹤0.01% 1427
2024
Q2 		$6.05M Sell
247,205
-3,307
-1% -$72.6K ﹤0.01% 1412
2024
Q1 		$5.34M Buy
250,512
+10,547
+4% +$227K ﹤0.01% 1475
2023
Q4 		$4.59M Buy
239,965
+15,308
+7% +$265K ﹤0.01% 1553
2023
Q3 		$3.6M Sell
224,657
-6,831
-3% -$130K ﹤0.01% 1620
2023
Q2 		$5.37M Sell
231,488
-5,653
-2% -$123K ﹤0.01% 1430
2023
Q1 		$5.51M Sell
237,141
-6,039
-2% -$123K ﹤0.01% 1365
2022
Q4 		$3.53M Buy
243,180
+6,106
+3% +$114K ﹤0.01% 1600
2022
Q3 		$4.52M Sell
237,074
-9,258
-4% -$212K ﹤0.01% 1412
2022
Q2 		$4.48M Buy
246,332
+4,506
+2% +$93.6K ﹤0.01% 1467
2022
Q1 		$6.09M Sell
241,826
-1,643
-0.7% -$42K ﹤0.01% 1413
2021
Q4 		$6.72M Buy
243,469
+25,473
+12% +$738K ﹤0.01% 1415
2021
Q3 		$7.04M Buy
217,996
+8,647
+4% +$287K ﹤0.01% 1356
2021
Q2 		$6.4M Sell
209,349
-50,206
-19% -$1.45M ﹤0.01% 1418
2021
Q1 		$7.9M Buy
259,555
+12,827
+5% +$364K ﹤0.01% 1348
2020
Q4 		$4.88M Buy
246,728
+1,198
+0.5% +$19.3K ﹤0.01% 1467
2020
Q3 		$3.2M Buy
245,530
+996
+0.4% +$12.6K ﹤0.01% 1558
2020
Q2 		$2.77M Buy
244,534
+15,284
+7% +$217K ﹤0.01% 1590
2020
Q1 		$3.28M Sell
229,250
-426
-0.2% -$9K ﹤0.01% 1361
2019
Q4 		$6.25M Buy
229,676
+19,671
+9% +$541K ﹤0.01% 1254
2019
Q3 		$6.01M Buy
210,005
+7,192
+4% +$210K ﹤0.01% 1202
2019
Q2 		$5.63M Buy
202,813
+5,857
+3% +$165K ﹤0.01% 1225
2019
Q1 		$6.54M Buy
196,956
+17,613
+10% +$536K ﹤0.01% 1037
2018
Q4 		$5.19M Buy
179,343
+13,488
+8% +$485K ﹤0.01% 1047
2018
Q3 		$7.65M Buy
165,855
+16,186
+11% +$720K 0.01% 968
2018
Q2 		$5.58M Buy
149,669
+8,207
+6% +$277K ﹤0.01% 1065
2018
Q1 		$4.18M Buy
141,462
+4,185
+3% +$142K ﹤0.01% 1186
2017
Q4 		$4.71M Buy
137,277
+1,856
+1% +$62.6K ﹤0.01% 1126
2017
Q3 		$4.9M Buy
135,421
+3,698
+3% +$105K ﹤0.01% 1037
2017
Q2 		$3.4M Buy
131,723
+10,023
+8% +$213K ﹤0.01% 1211
2017
Q1 		$2.34M Buy
121,700
+96,452
+382% +$1.71M ﹤0.01% 1379
2016
Q4 		$421K Buy
25,248
+7,562
+43% +$137K ﹤0.01% 2021
2016
Q3 		$366K Buy
17,686
+2,238
+14% +$56.8K ﹤0.01% 1847
2016
Q2 		$473K Hold
15,448
– – ﹤0.01% 1357
2016
Q1 		$577K Buy
15,448
+1,480
+11% +$55.8K ﹤0.01% 1264
2015
Q4 		$608K Buy
13,968
+937
+7% +$39.6K ﹤0.01% 1278
2015
Q3 		$485K Hold
13,031
– – ﹤0.01% 1304
2015
Q2 		$438K Buy
13,031
+10,923
+518% +$371K ﹤0.01% 1361
2015
Q1 		$75K Buy
+2,108
New +$75.4K ﹤0.01% 2231

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Legal & General Group's MYGN Position: Q2 2026 in Review

Legal & General Group reduced its Myriad Genetics (MYGN) stake by 65% in Q2 2026, selling an estimated $176K and leaving 21,005 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #2619.

Legal & General Group first reported a position in MYGN in Q1 2015 and has held it in 46 quarters since. The position peaked at $7.9M in Q1 2021. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Legal & General Group held 21,005 shares of Myriad Genetics worth $120K as of Q2 2026.
  • Legal & General Group sold 38,698 Myriad Genetics shares in Q2 2026, an estimated $176K.
  • Myriad Genetics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2619 holding.
  • Legal & General Group first reported a position in Myriad Genetics in Q1 2015 and has held it in 46 quarters since.
  • Legal & General Group's Myriad Genetics position peaked at $7.9M in Q1 2021.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.